Recent developments in biased agonism
Introduction
That a given G protein coupled receptor (GPCR) can functionally couple to more than one heterotrimeric G protein has been known for many years. However, it was quite surprising when it was first noted in the mid 1990s that, at a single GPCR, different ligands could be ‘biased’ or ‘functionally selective’ toward one or another of these G proteins. Even more surprising were the discoveries a few years later that GPCRs could also signal through β-arrestins and that ligands could be biased toward either a G protein or β-arrestin-mediated pathways. The study of this important and potentially therapeutically relevant phenomenon has exploded over the last several years. Here we review some of the most important recent developments.
In recent years the list of known biased ligands for GPCRs has grown substantially. While the majority of the ligands identified target the binding site of the endogenous ligand for a given receptor (known as orthosteric ligands), recent work has identified a new class of biased ligands, biased allosteric modulators, which bind non-traditional ligand binding sites topographically distinct from the orthosteric binding site [1]. Biased allosteric modulators are characterized by the ability to modulate agonist affinity and/or efficacy toward a biased receptor conformation without affecting receptor activity on their own. In addition to the discovery of a large number of biased ligands acting on multiple receptor types, several major advances have been made regarding the mechanisms underlying biased agonism.
Section snippets
Mechanistic insights into biased agonism
Different receptor states may vary in their ability to activate specific transducers such as G proteins or β-arrestins, as well as to affect transducer functionality in a selective manner. This is supported by the observation that β-arrestin function is dependent on the phosphorylation pattern or ‘barcode’ of the receptor to which it is recruited (Figure 1) [2, 3•, 4, 5]. Nobles et al. [3•] demonstrated that β-arrestin recruited to the β2-adrenergic receptor (β2AR) phosphorylated by either G
Quantification of ligand bias
Quantifying ligand bias is important not only to pharmacologically characterize a compound but also in the design of biased drugs, for example, for lead optimization and selection of candidate compounds. While qualitative approaches, such as a comparison of efficacies or an assessment of relative rank order of potencies [15, 16, 17], can identify extremely biased compounds, they usually cannot identify weakly biased compounds or compare different levels of bias between compounds. Thus,
Methodological advances
A common means of determining agonist efficacy for specific transducer pathways is by measurement of second messenger production or downstream signaling events in cell-based assays, such as by monitoring production of cAMP or phosphorylation of ERK1/2. However, downstream signals are often amplified to different extents depending on the assay being used [18•, 20, 21]. Thus, conclusions about transducer efficacy drawn solely based on downstream signaling events may be imprecise and misleading.
Conformational plasticity and multiple ligand-specific conformations of receptor enable biased GPCR signaling
The ‘two-state’ receptor model (inactive and active states) was previously widely accepted to explain GPCR conformation and function. In this model, all ligands with similar functional capabilities stabilize a common receptor conformation. However there is a growing body of evidence supporting ‘multi-state’ models in which GPCRs are dynamic proteins with a high level of plasticity, manifesting in thermally accessible multiple distinct ligand-specific conformations [26, 27•, 28, 29, 30, 31••, 32
Molecular and structural mechanisms underlying biased agonism
Recent structural determination efforts as well as biochemical and biophysical studies are beginning to shed light on the mechanisms by which biased ligands regulate receptor activity. The data suggest that conformational changes in transmembrane domain (TM) 7-helix (H) 8 and extracellular loop (ECL) 2 may all play a role in β-arrestin-mediated signaling, whereas conformational changes in TM3, 5 and 6 as well as intracellular loop (ICL) 3 have been associated with G protein-mediated signaling [
Clinical application
The recognition that biased ligands can activate distinct subsets of downstream signaling cascades relative to unbiased ligands has led to a paradigm shift in terms of how ligand efficacy is defined and characterized. In addition, it has stimulated significant interest in the potential clinical implications of these agents. Indeed recent evidence supports the hypothesis that biased ligands may possess unique pharmacologic properties compared to traditional unbiased ligands.
Over the past few
Conclusions
The classical paradigm of ligand efficacy has undergone major revisions over the past several years with the introduction of concepts such as biased agonism. The recognition that ligands can induce specific receptor activation profiles has stimulated significant interest in obtaining a better understanding of the physiologic, pharmacologic, structural and biophysical mechanisms underlying this phenomenology. Recent research has broadened the understanding of ligand bias and demonstrated that
References and recommended reading
Papers of particular interest, published within the period of review, have been highlighted as:
• of special interest
•• of outstanding interest
References (64)
Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling
Proc Natl Acad Sci U S A
(2005)A phosphorylation cluster of five serine and threonine residues in the C-terminus of the follicle-stimulating hormone receptor is important for desensitization but not for beta-arrestin-mediated ERK activation
Mol Endocrinol
(2006)- et al.
Measurements of ligand bias and functional affinity
Nat Rev Drug Discov
(2013) Multiple ligand-specific conformations of the beta2-adrenergic receptor
Nat Chem Biol
(2011)The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex
Proc Natl Acad Sci U S A
(2009)The dynamic process of beta(2)-adrenergic receptor activation
Cell
(2013)Biased suppression of TP homodimerization and signaling through disruption of a TM GxxxGxxxL helical interaction motif
J Lipid Res
(2013)Conformational ensemble view of G protein-coupled receptors and the effect of mutations and ligand binding
Methods Enzymol
(2013)Efficacy of the beta(2)-adrenergic receptor is determined by conformational equilibrium in the transmembrane region
Nat Commun
(2012)Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation
Nature
(2011)
Structural features for functional selectivity at serotonin receptors
Science
The structural basis for agonist and partial agonist action on a beta(1)-adrenergic receptor
Nature
Structural basis for molecular recognition at serotonin receptors
Science
Structure of class B GPCR corticotropin-releasing factor receptor 1
Nature
The beta-arrestin-biased ligand TRV120023 inhibits angiotensin II-induced cardiac hypertrophy while preserving enhanced myofilament response to calcium
Amer J Physiol Heart Circ Physiol
Allosteric modulation of G protein-coupled receptors
Ann Rev Pharmacol Toxicol
Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands
Proc Natl Acad Sci U S A
Distinct phosphorylation sites on the beta(2)-adrenergic receptor establish a barcode that encodes differential functions of beta-arrestin
Sci Signal
Arrestin binds to different phosphorylated regions of the thyrotropin-releasing hormone receptor with distinct functional consequences
Mol Pharmacol
Phosphorylation of the endogenous thyrotropin-releasing hormone receptor in pituitary GH3 cells and pituitary tissue revealed by phosphosite-specific antibodies
J Biol Chem
Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor
Proc Natl Acad Sci U S A
Beta-arrestin-dependent: G protein-independent ERK1/2 activation by the beta2 adrenergic receptor
J Biol Chem
A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling
Proc Natl Acad Sci U S A
A biased ligand for OXE-R uncouples Galpha and Gbetagamma signaling within a heterotrimer
Nat Chem Biol
Crystal structure of the beta2 adrenergic receptor-Gs protein complex
Nature
Gi protein activation in intact cells involves subunit rearrangement rather than dissociation
Proc Natl Acad Sci U S A
G Protein activation without subunit dissociation depends on a G{alpha}(i)-specific region
J Biol Chem
Signalling bias in new drug discovery: detection, quantification and therapeutic impact
Nat Rev Drug Discov
A simple method for quantifying functional selectivity and agonist bias
ACS Chem Neurosci
Quantifying ligand bias at seven-transmembrane receptors
Mol Pharmacol
Quantifying biased agonism: understanding the links between affinity and efficacy
Nat Rev Drug Discov
Teaching old receptors new tricks: biasing seven-transmembrane receptors
Nat Rev Drug Discov
Cited by (235)
The formyl peptide receptors FPR1 and FPR2 as targets for inflammatory disorders: recent advances in the development of small-molecule agonists
2024, European Journal of Medicinal ChemistryAn insight review on the neuropharmacological effects, mechanisms of action, pharmacokinetics and toxicity of mitragynine
2024, Biomedicine and PharmacotherapyPhospholipase signaling in inflammation and promiscuity of phospholipase active site ligands
2023, Phospholipases in Physiology and Pathology: Volumes 1-7Biased agonists differentially modulate the receptor conformation ensembles in Angiotensin II type 1 receptor
2023, Journal of Molecular Graphics and ModellingBioactivity of 11 keto and hydroxy androgens in yeast and mammalian host cells
2022, Journal of Steroid Biochemistry and Molecular Biology